MEK inhibitors have long been tested in uveal melanoma due to the activation of the MAPK pathway by GNAQ. So far, only a limited efficacy of MEK inhibitors was detected, in immune therapy naive patients with classical GNAQ mutations [26,27,28]. Here, MAP2K7 is linked to uveal melanoma.